

To contact NHS BSW ICB Medicines Optimisation Team:

✉ bswicb.prescribing@nhs.net

Website: <https://bswtogether.org.uk/medicines/>

BSW Area Prescribing Committee (APC) Updates

All recent decisions made by the BSW APC can be read in full [here](#) or in the newsfeed of the [BSWformulary homepage](#)

New additions to BSW formulary

- [Contour Next blood glucose test strips](#) Added with **AMBER** TLS, but only for patients under the supervision of the RUH gestational diabetes clinic and using a Contour Next meter connected to the GDM-health gestational diabetes app.

New and Updated Shared Care Agreements and Prescribing Guidance

- **UPDATE** – [Sildenafil for digital ulceration/management of severe Raynaud's phenomenon in adults with Connective Tissue Disease \(unlicensed indication\)](#) Update includes minor reformatting and corrected contact details.
- **CHANGE IN TLS** – [Relugolix-estradiol-norethisterone acetate \(Ryeqo®\)](#) Changed from RED to **AMBER** TLS. After a minimum one month's treatment, Ryeqo may now be prescribed in primary care. Also see **NEW** [BSW Prescribing guidance for relugolix-estradiol-norethisterone acetate \(Ryeqo®\) for treatment of uterine fibroids](#).
- **UPDATE** – [Inclisiran Guidance for Primary Care](#) Update reflects the NHSE change in reimbursement price.
- **UPDATE** – [Initiating SGLT2's in adults with T2D](#) Minor update to formatting.

Removed from BSW formulary

- [Methylcellulose](#) tablets, [Normacol®](#) sachets, [miconazole](#) vaginal cream, [colestipol](#) sachets. Removed from formulary as discontinued by manufacturer.

Aligned on BSW formulary

- [Almotriptan](#) 12.5mg tablets **GREEN** TLS
- [Ganciclovir](#) 0.15% eye gel – **AMBER** TLS (adults)
- [Aciclovir](#) 3% eye ointment – **AMBER** TLS (paeds)
- [Sodium chloride](#) 5% eyedrops and PF eye ointment – **AMBER** TLS
- [Itraconazole](#) oral suspension, aligned with **AMBER** TLS and [Cefixime](#) tablets, [benzathine benzylpenicillin](#) injection, [imipenem/cilastatin](#) injection, [daptomycin](#) injection, [Voractiv®](#) tablets, [moxifloxacin](#) tablets, [famciclovir](#) tablets, [atovaquone](#) oral suspension, all aligned with **RED** TLS. This follows routine review of Chapter 5. Please also see individual formulary entries for more information as some RED TLS antimicrobials are restricted to use ONLY after specialist micro advice and may not be routinely stocked within all Trusts.

What the BSW CCG formulary team are currently working on

- Incorporating guanfacine into the existing paediatric ADHD SCA.
- Working with endocrinology teams across BSW on a new SCA for cinacalcet for primary hyperparathyroidism in adults.
- Working with local and regional specialist renal and diabetes teams on prescribing information to support the implementation of finerenone for treating chronic kidney disease in T2D as per NICE [Overview | Finerenone for treating chronic kidney disease in type 2 diabetes | Guidance | NICE](#)

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net

[Medicines Optimisation website](#)

[New documents](#)

NEW FEATURE [MOCH Quarterly Newsletter- MOCH Quarterly Newsletter – Spring 2023](#)

[FDB Optimise](#), adding button to toolbar -[FDB Optimise Rx Adding an FDB button to toolbar](#)

[MOCH Medication Administration Record \(MAR\) Charts in Care Homes: -MOCH Medication Administration Record \(MAR\) Charts in Care Homes: Good Practice Guidance](#)
[MOCH Fridge Temperature -MOCH Fridge Temperature Out of Range Flowchart](#)

[Updated documents](#)

[PrescQIPP Impact - PrescQIPP Impact – Improving Medicines & Polypharmacy Appropriateness Clinical Tool](#)

[Environmental impact of inhalers - Environmental impact of inhalers – patient information leaflet](#)

[Prescribe Well Spend Less \(PWSL\) \(May 2023\)-BSW Prescribing 2023-24 Savings Recommendations Prescribe Well – Spend Less \(May 2023\)](#)

[Prescribing Guidance for Moderately to Severely Frail Patients-BSW Prescribing Guidance for Moderately to Severely Frail Patients \(April 2023\)](#)

MHRA – safety reminders

[Nitrofurantoin- reminder of risks](#)-Healthcare professionals prescribing nitrofurantoin should be alert to the risks of pulmonary and hepatic adverse drug reactions and advise patients to be vigilant for the signs and symptoms in need of further investigation <https://www.gov.uk/drug-safety-update/nitrofurantoin-reminder-of-the-risks-of-pulmonary-and-hepatic-adverse-drug-reactions>

Influenza season 2022/23: **ending the prescribing** and supply of antiviral medicines

The most recent surveillance data from UK Health Security Agency (UKHSA) indicates that circulation of influenza in the community has returned to baseline levels. In accordance with NICE guidance and Schedule 2 to the National Health Service (General Medical Services Contracts) (Prescription of drugs etc.) Regulations 2004, commonly known as the Grey List or Selected List Scheme (SLS):

- GPs and other prescribers working in primary care should no longer prescribe antiviral medicines (including neuraminidase inhibitors) for the prophylaxis and treatment of influenza on an FP10 prescription form.
- Community pharmacists should no longer supply antiviral medicines in primary care on presentation of an FP10 prescription form.

This advice stands until a notification is issued to re-commence prescribing and supply of antiviral medicines in primary care. This does not impact on prescribing of antiviral medicines in hospitals, which can continue as normal.

Further information, including the arrangements for prescribing antiviral medicines for localised community outbreaks, is provided [here](#)

££££££££ Cost Saving drug switch of the month: generic carbomer 980/ Artelac Nighttime/ Gel Tears/ Ocufresh Gel/ Xailin Gel ALL to ACOMER brand ££££££££

Drug	Cost	Quantity	Switched To	Cost	Quantity	Saving per bottle
Generic carbomer 980 0.2% eye drops (generic)	£2.80	10 grams	Acomer	£1.34	10 grams	£1.46
Artelac Nighttime 0.2% gel	£2.96	10 grams	Acomer	£1.34	10 grams	£1.62
Gel Tears 0.2% eye gel	£2.80	10 grams	Acomer	£1.34	10 grams	£1.46
Ocufresh 0.2% lubricating eye gel	£2.80	10 grams	Acomer	£1.34	10 grams	£1.46
Xailin 0.2% eye gel	£3.43	10 grams	Acomer	£1.34	10 grams	£2.09

Please see our recently **updated dry eye guidance** for further information [here](#).

At the **end of each financial quarter** please remember to **complete and submit the cost savings recording template** which accompanied the Q2 report to bswibc.prescribing@nhs.net

West of England Polypharmacy Community of Practice session

Thursday 15th of June 12:00 – 13:30 ‘The subtle art of conversation around medicines optimisation; Can medicines optimisation be achieved without optimising conversations?’ In the session, you will:

- Hear what the evidence says about effective phrases and terminology to use when entering shared-decision making conversations
- Hear from people with lived experience (positive and negative) of polypharmacy
- Based on feedback, understand what patients on long term medicines would want clinicians to know
- An opportunity to ask open questions to people with lived experience of taking multiple medicines
- Have opportunities to discuss openly with other colleagues
- Carry out activities to share learning and develop shared ideas

[Register here](#)

New AHSN pathways

The AHSNs have developed two pathways to support healthcare professionals in implementing NICE and other relevant evidence in **lipid management** in secondary prevention. One pathway is for acute cardiovascular disease in secondary care [Pathway for secondary care – following an Acute Cardiovascular Event](#) and one is for **primary care clinicians** [Pathway for primary care – for Secondary Prevention in Primary Care](#). These provide guidance on how optimal lipid management may be achieved and are supported by our local lipid specialist teams. General background information about the guidance can be found [Here](#)

Recall Of Emerade 500 Micrograms And Emerade 300 Micrograms Auto-Injectors

Via the usual Central Alerting System (CAS) cascade process practices should have received this Class 1 *patient level* Medicines Recall for all Emerade 500 Microgram and Emerade 300 Microgram (adrenaline) auto-injectors and an associated National Patient Safety Alert (see email below). A potential for **device failure** has been identified.

Please read the documents attached to the CAS alert below for FULL information on actions required, links to a patient letter and patient training materials on how to use the alternative brands of adrenaline auto-injectors.

Patients, or carers of patients, who carry Emerade 300 or 500 microgram auto-injector pens require a prescription and supply of two auto-injector pens of an alternative brand. Once they have received a new supply of an alternative brand, they should then return their Emerade 300 or 500 microgram pens to their local pharmacy.

At the point of prescribing and dispensing, it is vital that patients and carers receive training to ensure they are completely familiar with how their new device works. This is because each brand of adrenaline auto-injector works differently. **Epipen** and **Jext** brands of adrenaline auto-injectors are considered suitable for prescribing across BSW https://bswformulary.nhs.uk/Adrenaline_Autoinjectors

- [Class-1-2023-004-MHRA.pdf](#)
- [Letter - Advice for patients who have been prescribed an Emerade auto-injectors.pdf](#)
- [NatPSA-2023-004-MHRA.pdf](#)

ALSO - MHRA – safety reminders- AAI safety campaign-The MHRA have summarised information for patients, healthcare professionals and the wider public to help better understand the importance of **AAIs as a potential life-saving medicine**. See [Adrenaline Auto-Injectors \(AAIs\) safety campaign](#)-The content has a patient friendly video on use of AAI , Infographic and links to national allergy charities

Clinical Examination Skills Training for Community Pharmacists

NHS England are making available 10,000 module places which will be delivered by CliniSkills until March 2024.

This exciting new training offer will give community pharmacists the opportunity to build on their existing clinical examination and consultation skills - to assess, treat and manage common health problems.

This offer is available to community pharmacists, including part-time staff and locums working in community pharmacy. For more information, visit the CliniSkills website at <https://www.cliniskills.com/>.

Anti-depressant Switching Guidance

Switching antidepressants – The SPS website has a suite of resources that give guidance on establishing whether a switch is necessary, choosing an antidepressant to switch to, agreeing a strategy, and monitoring. They also give advice on suitable strategies for a range of potential switches- [Here](#)

Enteral feeds – reminder **not to prescribe** on FP10

All prescribing for enteral feeds should come from the local **Dietetic Home Enteral Feeding Service**. Please note this does not include oral nutritional supplements (ONS). BSW MO team have created an OptimiseRx message which should alert prescribers in the event of trying to issue a prescription for an enteral feed

Patients or their representatives can **contact their local service** directly :

Bath - 0117 342 7515

Swindon - 01793 605143

Wiltshire - 01249 456512